Web Desc
Cancer Vaccines
Organizer(s): Lélia Delamarre, Robert A. Seder and Nina Bhardwaj
Date: January 20 - 24, 2019
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
Organized in collaboration with Cancer Research UK

Sponsored by BioLegend, Inc., Genentech, Inc. and Pfizer Inc.
For important information on the coronavirus, please click here
Summary of Meeting:
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.
Scholarship Deadline: October 16 2018
Discounted Abstract Deadline: October 16 2018
Abstract Deadline: October 24 2018
Discounted Registration Deadline: November 27 2018
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.Organized in collaboration with Cancer Research UKGenentech, Inc.Pfizer Inc.
We gratefully acknowledge additional support for this conference from:
American Society of Gene & Cell Therapy (ASGCT)Genocea Biosciences
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Novartis Institutes for BioMedical Research
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA236283-01
Funding for this conference was made possible (in part) by 1R13CA236283-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 20 | 4:00PM - 8:00PM
Arrival and Registration
Room: Pacific Ballroom Foyer


Sunday, January 20 | 6:00PM - 8:00PM
Welcome Mixer
Room: Pacific Ballroom Foyer
No registration fees are used to fund alcohol served at this function.

Monday, January 21 | 7:30AM - 8:30AM
Breakfast
Room: Vancouver Island/Waddington


Monday, January 21 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Pacific Ballroom

Speaker 1 of 6
* Lélia Delamarre, Genentech, Inc., USA

Monday, January 21 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Pacific Ballroom

Speaker 2 of 6
* Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA

Monday, January 21 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Pacific Ballroom

Speaker 3 of 6
* Robert A. Seder, NIAID, National Institutes of Health, USA

Monday, January 21 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Pacific Ballroom

Speaker 4 of 6
Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Cancer Vaccines: Overview

Monday, January 21 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Pacific Ballroom

Speaker 5 of 6
Ira Mellman, Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy

Monday, January 21 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Pacific Ballroom


Coffee Break

Monday, January 21 | 10:20AM - 12:30PM
Identification of Mutated Neoantigens
Room: Pacific Ballroom

Speaker 1 of 6
* Glenn Dranoff, Novartis Institutes for BioMedical Research, USA

Monday, January 21 | 10:20AM - 12:30PM
Identification of Mutated Neoantigens
Room: Pacific Ballroom

Speaker 2 of 6
Timothy A. Chan, Memorial Sloan Kettering Cancer Center, USA
Mutations and Neoantigens in Cancer Immunotherapy

Monday, January 21 | 10:20AM - 12:30PM
Identification of Mutated Neoantigens
Room: Pacific Ballroom

Speaker 3 of 6
Karin U. Jooss, Gritstone Oncology, USA
Driving CD8+ T Cell Responses to Mutational Neoantigens in Tumors - Harnessing Immunogenic Viral Vectors

Monday, January 21 | 10:20AM - 12:30PM
Identification of Mutated Neoantigens
Room: Pacific Ballroom

Speaker 4 of 6
Lélia Delamarre, Genentech, Inc., USA
Determinants of Cancer Neoantigen Immunogenicity

Monday, January 21 | 10:20AM - 12:30PM
Identification of Mutated Neoantigens
Room: Pacific Ballroom

Speaker 5 of 6
Binbin Chen, Stanford Medical School, USA
Short Talk: MARIA: Deep Neural Network Predicting HLA Class II Antigen Presentation for Personalized Cancer Vaccines

Monday, January 21 | 10:20AM - 12:30PM
Identification of Mutated Neoantigens
Room: Pacific Ballroom

Speaker 6 of 6
Lisa McNeil, Genocea Biosciences, USA
Short Talk: ATLAS™ Identifies Stimulatory and Inhibitory Neoantigens with Opposing Effects in a Murine Challenge Model

Monday, January 21 | 12:30PM - 5:00PM
On Own for Lunch


Monday, January 21 | 12:30PM - 1:00PM
Poster Setup
Room: Pacific Ballroom


Monday, January 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Pacific Ballroom


Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Cancer Antigens and Immune Monitoring
Room: Pacific Ballroom

Speaker 1 of 6
Samuel J. Landry, Tulane University Health Sciences Center, USA
CD4+ Epitope Prediction Limited by Analysis of Antigen Conformational Flexibility

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Cancer Antigens and Immune Monitoring
Room: Pacific Ballroom

Speaker 2 of 6
* Aude-Helene Capietto, Genentech, Inc., USA
Characterization of the Immunogenic Determinants of Tumor Neoantigens Improves their Identification

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Cancer Antigens and Immune Monitoring
Room: Pacific Ballroom

Speaker 3 of 6
Cansu Cimen Bozkus, Icahn School of Medicine at Mount Sinai, USA
Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Cancer Antigens and Immune Monitoring
Room: Pacific Ballroom

Speaker 4 of 6
Russell Kent Pachynski, Washington University in St. Louis, USA
A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Cancer Antigens and Immune Monitoring
Room: Pacific Ballroom

Speaker 5 of 6
Brandon Coder, Advaxis, USA
Neoantigen Prioritization for Use in a Listeria Monocytogenes Cancer Vaccine

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Cancer Antigens and Immune Monitoring
Room: Pacific Ballroom

Speaker 6 of 6
Ghislain Bonamy, immunoSCAPE, Singapore
Leveraging the Multi-Parametric Profiling Capacity of Mass Cytometry to Query the Specificity of Tumor-Infiltrating T-Cells

Monday, January 21 | 4:30PM - 5:00PM
Coffee Available
Room: Pacific Ballroom Foyer


Monday, January 21 | 5:00PM - 7:00PM
Other Cancer Antigens
Room: Pacific Ballroom

Speaker 1 of 5
* Lélia Delamarre, Genentech, Inc., USA

Monday, January 21 | 5:00PM - 7:00PM
Other Cancer Antigens
Room: Pacific Ballroom

Speaker 2 of 5
Stephen B. Baylin, Johns Hopkins University School of Medicine, USA
Immunogenicity of Transposable Elements in Cancer – Relevance to Epigenetic Therapy

Monday, January 21 | 5:00PM - 7:00PM
Other Cancer Antigens
Room: Pacific Ballroom

Speaker 3 of 5
Victor H. Engelhard, University of Virginia, USA
Post-Translationally Modified Cancer Neoantigens

Monday, January 21 | 5:00PM - 7:00PM
Other Cancer Antigens
Room: Pacific Ballroom

Speaker 4 of 5
Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA
Targeting HPV Antigens by Vaccination

Monday, January 21 | 5:00PM - 7:00PM
Other Cancer Antigens
Room: Pacific Ballroom

Speaker 5 of 5
Haiyin Chen, Genentech, Inc., USA
Short Talk: Transposable Element Expression in Tumors Is Associated with Immune Infiltrate and Increased Antigenicity

Monday, January 21 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Vancouver Island/Waddington
No registration fees are used to fund alcohol served at this function.

Monday, January 21 | 7:30PM - 10:00PM
Poster Session 1
Room: Pacific Ballroom


Tuesday, January 22 | 7:30AM - 8:30AM
Breakfast
Room: Vancouver Island/Waddington


Tuesday, January 22 | 8:00AM - 8:30AM
Poster Setup
Room: Pacific Ballroom


Tuesday, January 22 | 8:30AM - 5:00PM
Poster Viewing
Room: Pacific Ballroom


Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 1 of 8
* Sebastian Amigorena, Institut Curie, France

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 2 of 8
Rafi Ahmed, Emory University School of Medicine, USA
T Cell Exhaustion and PD-1 Immunotherapy

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 3 of 8
E. John Wherry, University of Pennsylvania, USA
The Developmental Program of Exhausted T Cells

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom


Coffee Break

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 5 of 8
Pedro Romero, University of Lausanne, Switzerland
Programming T Cell Memory for Immunotherapy of Cancer

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 6 of 8
David B. Masopust, University of Minnesota, USA
Repurposing Antiviral T Cells to Fight Tumors

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 7 of 8
John P. Finnigan, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Molecular and Cellular Properties of Neoantigen-Specific CD8+ T Cells Interacting with Melanoma in situ

Tuesday, January 22 | 8:30AM - 11:30AM
Priming T Cells
Room: Pacific Ballroom

Speaker 8 of 8
Jared Klarquist, University of Colorado Denver, USA
Short Talk: Vaccine-Elicited T Cells Expand and Function Independently of Aerobic Glycolysis: Implications for Therapeutic Cancer Vaccines

Tuesday, January 22 | 11:30AM - 12:30PM
Lunch
Room: Vancouver Island/Waddington


Tuesday, January 22 | 12:00PM - 2:30PM
Poster Session 2
Room: Pacific Ballroom


Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 1 of 8
* Karin Loré, Karolinska Institutet, Sweden

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 2 of 8
Jaehak Oh, Genentech, Inc., USA
RNA-Lipoplex Vaccine Is Presented on MHCI and MHCII Molecules of Differential Dendritic Cell Subsets in Spleen

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 3 of 8
Yanling Xiao, Netherlands Cancer Institute, Netherlands
Antigen Cross-Presentation and T-Cell Priming Ability of Human Dendritic Cells Generated in vitro from a Newly Discovered Oligopotent Progenitor of Granulocytes, Macrophages, Osteoclasts and Dendritic Cells

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 4 of 8
Faezzah Baharom, National Institutes of Health, USA
Route, Dose and Agonist Potency Influence the Induction of TCF1+ Neoantigen-Specific CD8 T Cells by Peptide-TLR7/8 Agonist Nanoparticle Vaccine

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 5 of 8
Anna Morena D'Alise, Nouscom Srl, Italy
Novel Adenovector Vaccine Targeting Multiple Neoantigens Eeradicates
Large Tumors in Mice in Combination with Checkpoint Blockade


Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 6 of 8
Robert Petit, Advaxis Inc., USA
Magnitude of Anti-PSA T Cell Response Is Associated with Antigen Spreading and Slowing in PSA and PAP Velocity

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 7 of 8
Alessia Melacarne, Humanitas University, Italy
Antigens Released by Salmonella-Infected Tumor Cells as a Novel Vaccine Platform

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Vaccine Platforms
Room: Pacific Ballroom

Speaker 8 of 8
Aymen Al-shamkhani, University of Southampton, UK
The Effects of Akt/Protein Kinase B on Effector and Memory CD8 T Cell Differentiation Revealed by Single Cell RNA-Seq

Tuesday, January 22 | 4:30PM - 5:00PM
Coffee Available
Room: Pacific Ballroom Foyer


Tuesday, January 22 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Pacific Ballroom

Speaker 1 of 6
* Ira Mellman, Genentech, Inc., USA

Tuesday, January 22 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Pacific Ballroom

Speaker 2 of 6
Karin Loré, Karolinska Institutet, Sweden
Understanding Innate Immune Mechanisms Dictating Vaccine Responses

Tuesday, January 22 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Pacific Ballroom

Speaker 3 of 6
Sebastian Amigorena, Institut Curie, France
Dendritic Cell Biology

Tuesday, January 22 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Pacific Ballroom

Speaker 4 of 6
Marc Y. Dalod, Centre National de la Recherche Scientifique, France
Deciphering the Role of cDC1 in Anti-Tumor Immunity

Tuesday, January 22 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Pacific Ballroom

Speaker 5 of 6
Zwi N. Berneman, Antwerp University Hospital, Belgium
Short Talk: Vaccination of Cancer Patients with WT1 mRNA-Electroporated Dendritic Cells: Correlation of Clinical Effect and
Overall Survival with T-Cell Response


Tuesday, January 22 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Pacific Ballroom

Speaker 6 of 6
Matthew G. Booty, SQZ Biotechnologies, USA
Short Talk: SQZ'ing Cells to Engineer a New Generation of Cancer Vaccines

Tuesday, January 22 | 7:00PM - 7:00PM
On Own for Dinner


Wednesday, January 23 | 7:30AM - 8:30AM
Breakfast
Room: Vancouver Island/Waddington


Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom

Speaker 1 of 7
* Catherine J. Wu, Dana-Farber Cancer Institute, USA

Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom

Speaker 2 of 7
David B. Weiner, Wistar Institute, USA
DNA-Based Vaccines

Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom

Speaker 3 of 7
John C. Bell, Ottawa Hospital Research Institute, Canada
Virus-Based Vaccines

Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom


Coffee Break

Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom

Speaker 5 of 7
Ugur Sahin, BioNTech AG, Germany
RNA-Based Vaccines

Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom

Speaker 6 of 7
Robert A. Seder, NIAID, National Institutes of Health, USA
Peptide-TLR 7/8 Agonist Vaccines Chemically Programmed to Enhance the Magnitude, Quality and Breadth of Neoantigen CD8 T Cell Responses

Wednesday, January 23 | 8:30AM - 11:30AM
Novel Cancer Vaccine Platforms I
Room: Pacific Ballroom

Speaker 7 of 7
Christian J. Maine, Janssen R&D, USA
Short Talk: Self-Amplifying RNA Polytope Vaccines Can Elicit Anti-Tumor T Cell Responses Against Neoantigens for Cancer Immunotherapy

Wednesday, January 23 | 11:30AM - 5:00PM
On Own for Lunch


Wednesday, January 23 | 4:30PM - 5:00PM
Coffee Available
Room: Pacific Ballroom Foyer


Wednesday, January 23 | 5:00PM - 7:00PM
Novel Cancer Vaccine Platforms II
Room: Pacific Ballroom

Speaker 1 of 5
* Robert A. Seder, NIAID, National Institutes of Health, USA

Wednesday, January 23 | 5:00PM - 7:00PM
Novel Cancer Vaccine Platforms II
Room: Pacific Ballroom

Speaker 2 of 5
Catherine J. Wu, Dana-Farber Cancer Institute, USA
Building Better Personal Cancer Vaccines

Wednesday, January 23 | 5:00PM - 7:00PM
Novel Cancer Vaccine Platforms II
Room: Pacific Ballroom

Speaker 3 of 5
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
DC Targeted Vaccines

Wednesday, January 23 | 5:00PM - 7:00PM
Novel Cancer Vaccine Platforms II
Room: Pacific Ballroom

Speaker 4 of 5
Joshua Tobias, Medical University of Vienna, Austria
Short Talk: A Paradigm Change in Cancer Immunotherapy: Combined B Cell Epitope Peptides of Her-2/neu and Immune
Checkpoint Inhibitors for Active Immunization


Wednesday, January 23 | 5:00PM - 7:00PM
Novel Cancer Vaccine Platforms II
Room: Pacific Ballroom

Speaker 5 of 5
Mubeen M. Mosaheb, Duke University, USA
Short Talk: A Poliovirus-Based Recombinant Vector Activates Antigen-Presenting Cells and Primes Anti-Tumor T Cell Immunity

Wednesday, January 23 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Vancouver Island/Waddington
No registration fees are used to fund alcohol served at this function.

Thursday, January 24 | 7:30AM - 8:30AM
Breakfast
Room: Vancouver Island/Waddington


Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 1 of 8
* Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA

Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 2 of 8
Joshua D. Brody, Icahn School of Medicine at Mount Sinai, USA
In situ Vaccination for Cancer

Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 3 of 8
Shannon J. Turley, Genentech, Inc., USA
TGFbeta in Cancer

Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom


Coffee Break

Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 5 of 8
Thomas Gajewski, University of Chicago, USA
Downstream Regulation at the Level of the Tumor Microenvironment

Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 6 of 8
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combination Therapies Inducing a Self-Sustaining Vaccinal Cycle

Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 7 of 8
Linda Hammerich, Icahn School of Medicine at Mount Sinai, USA
Short Talk: In situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors via Induction of
Antigen Cross-Presentation by Dendritic Cells


Thursday, January 24 | 8:30AM - 11:30AM
Tumor Microenvironment and Combination Therapies
Room: Pacific Ballroom

Speaker 8 of 8
Bin Liu, University of California, Los Angeles, USA
Short Talk: Combination of in situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) and Anti-PD1 for Non-Small Cell Lung Cancer (NSCLC)

Thursday, January 24 | 11:30AM - 5:00PM
On Own for Lunch


Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Combination Therapies
Room: Pacific Ballroom

Speaker 1 of 6
* Joshua D. Brody, Icahn School of Medicine at Mount Sinai, USA

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Combination Therapies
Room: Pacific Ballroom

Speaker 2 of 6
Selma Bekri, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of a Neoantigen Vaccine for Multiple Myeloma

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Combination Therapies
Room: Pacific Ballroom

Speaker 3 of 6
Elham Beyranvand Nejad, Leiden University Medical Center, Netherlands
Non-Curative Immunotherapy Drives the Development of Immune-Deserted Recurrences

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Combination Therapies
Room: Pacific Ballroom

Speaker 4 of 6
Rosmely Hernandez, University of Miami Miller School of Medicine, USA
IL-2-Dependent Amplification of T Effector and Memory Responses to Promote Anti-Tumor Immunity

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Combination Therapies
Room: Pacific Ballroom

Speaker 5 of 6
Zhen Zeng, University of Queensland, Australia
The Involvement of IFN-? and CXCR3 in the CD8+ T-Cell-Mediated Regression of Squamous Cell Carcinoma

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Combination Therapies
Room: Pacific Ballroom

Speaker 6 of 6
Ramin Salehi-Rad, University of California, Los Angeles, USA
Tumor Vaccination with CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Checkpoint Blockade in Murine Models of NSCLC with Varying Mutational Load

Thursday, January 24 | 4:30PM - 5:00PM
Coffee Available
Room: Pacific Ballroom Foyer


Thursday, January 24 | 5:00PM - 6:45PM
Immune Monitoring of T Cells
Room: Pacific Ballroom

Speaker 1 of 4
Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers

Thursday, January 24 | 5:00PM - 6:45PM
Immune Monitoring of T Cells
Room: Pacific Ballroom

Speaker 2 of 4
Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
NKG2A Blockade Potentiates CD8+ T-Cell Immunity Induced by Therapeutic Cancer Vaccines

Thursday, January 24 | 5:00PM - 6:45PM
Immune Monitoring of T Cells
Room: Pacific Ballroom

Speaker 3 of 4
* Evan W. Newell, Fred Hutchinson Cancer Research Center, USA
Asking T Cells About What They See in Cancer

Thursday, January 24 | 5:00PM - 6:45PM
Immune Monitoring of T Cells
Room: Pacific Ballroom

Speaker 4 of 4
Mark Klinger, Adaptive Biotechnologies, USA
Short Talk: Optimization of Cancer Vaccine Development by using Multiplexed Identification of T-Cell Receptor Antigen Specificity (MIRA)

Thursday, January 24 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Pacific Ballroom


Thursday, January 24 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, January 24 | 8:00PM - 11:00PM
Entertainment
Room: Pacific Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, January 24 | 8:00PM - 11:00PM
Cash Bar
Room: Pacific Ballroom


Friday, January 25 | 10:24AM - 10:24AM
Departure


*Session Chair
†Invited, not yet responded.